FDA warning on Depo-Provera could hit Teva sales

Globes Gorrespondent, "FDA warning on Depo-Provera could hit Teva sales. The contraceptive will now carry a "black box" warning because of the risk of bone weakening" (18 Nov 2004, Globes online)
Leading text: "Yesterday, the US Food and Drug Administration (FDA) issued a warning that about contraceptive Depo-Provera that could affect sales by Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA), which produces a generic version of the drug. The FDA warned that long-term use of Depo-Provera can cause irreversible weakening of bones. The drug will now carry a "black box" designation, meaning that it should be prescribed only with great care..." [FullText]